Millions of People Could Live Thanks to New Access to Tuberculosis Medication

Johnson & Johnson has made a big decision to stop enforcing its patents.

Patrick Pleul/AP

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily.

Johnson & Johnson announced on Friday that the company will not enforce patents for the lifesaving tuberculosis treatment bedaquiline in 134 low- and middle-income countries globally. Bedaquiline, which was approved in 2012, is an essential part of treatment for multidrug-resistant tuberculosis, also known as MDR-TB. MDR-TB impacts half a million people annually, and 200,000 of those infected will die.

Bedaquiline was the first new tuberculosis drug to become available in around forty years, and its development was a major step forward in treating the deadly illness. But for millions of patients globally, the drug has been out of reach. Johnson & Johnson’s patent prevented cost-effective generic versions of the drug from being available to many in lower-income countries where tuberculosis is most prevalent and most deadly. 

The announcement from Johnson & Johnson has the potential to reduce the price of bedaquiline by at least 50 percent, greatly increasing the availability of the drug globally. Johnson & Johnson has faced immense pressure to give up control of its patent from organizations like Doctors Without Borders and Partners in Health. Doctors Without Borders began a public campaign against the company in 2019, arguing that because taxpayers had invested five times more in the development of bedaquiline than Johnson & Johnson, it was wrong for the corporation to control the price of the drug.

Those advocates are now celebrating a major step towards treating tuberculosis globally. “Johnson & Johnson’s announcement is a heartening example of solidarity, and one that will make a real difference in the lives of the half-million people who newly fall sick with MDR-TB each year,” said Partners In Health CEO Dr. Sheila Davis in a statement. 

The hugely popular author and YouTuber John Green has also been extremely vocal about pressuring Johnson & Johnson to drop enforcement of their patent, recently penning a piece for the Washington Post about his experience visiting a tuberculosis treatment center in Sierra Leone in 2019. On Saturday, he celebrated the enormous victory on YouTube. “This is the announcement that we have been waiting for and that I have to confess, despite my ridiculous over-the-top optimism about all this stiff never thought was possible.”

 

Owned by no one—except you.

We just keep seeing it happen: Newsrooms owned by billionaires and corporations are spinning their own narratives, overwriting the truth, following only stories that keep them in the pocket of those with even more power.

Not here. We’re not owned by anyone. We’re not part of any cult that demands our allegiance to a bottom line. We’ve spoken up and spoken out while other newsrooms changed their stories—or cut them altogether—to keep the C suite happy.

Our mission is to find the truth and amplify it. That’s why we’re independent, nonprofit, and, crucially, funded by readers. The investigations on our website will always be free to read, watch, and listen to, but our newsroom is powered by readers who pitch in what they can so we can keep asking the hard questions.

Can you chip in today?

Owned by no one—except you.

We just keep seeing it happen: Newsrooms owned by billionaires and corporations are spinning their own narratives, overwriting the truth, following only stories that keep them in the pocket of those with even more power.

Not here. We’re not owned by anyone. We’re not part of any cult that demands our allegiance to a bottom line. We’ve spoken up and spoken out while other newsrooms changed their stories—or cut them altogether—to keep the C suite happy.

Our mission is to find the truth and amplify it. That’s why we’re independent, nonprofit, and, crucially, funded by readers. The investigations on our website will always be free to read, watch, and listen to, but our newsroom is powered by readers who pitch in what they can so we can keep asking the hard questions.

Can you chip in today?

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

INDEPENDENT. BECAUSE OF YOU.

Mother Jones has no billionaires calling the shots—just readers like you making fearless reporting possible

Donate